Market Place
Sourcing Support
SpringWorks Reports Q3 2024 Financial Results & Highlights
12 Nov 2024 //
GLOBENEWSWIRE
SpringWorks to Participate in Jefferies London Conference
12 Nov 2024 //
GLOBENEWSWIRE
SpringWorks Publishes Phase 2b ReNeu Results in Clinical Oncology
11 Nov 2024 //
GLOBENEWSWIRE
SpringWorks to Present Mirdametinib Data at SNO 2024
11 Nov 2024 //
GLOBENEWSWIRE
SpringWorks Reports Data on OGSIVEO in Desmoid Tumors at CTOS 2024
07 Nov 2024 //
GLOBENEWSWIRE
SpringWorks Joins Guggenheim Healthcare Innovation Conference
05 Nov 2024 //
GLOBENEWSWIRE
SpringWorks To Report Q3 2024 Results On Nov 12
22 Oct 2024 //
GLOBENEWSWIRE
FDA Grants Priority Review To SpringWorks` NDA For Mirdametinib
28 Aug 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics Reports Q2 2024 Results And Business Highlights
07 Aug 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics Appoints Dr. Martin Mackay to its Board of Directors
29 Jul 2024 //
GLOBENEWSWIRE
SpringWorks To Report Q2 2024 Results On August 7
23 Jul 2024 //
GLOBENEWSWIRE
SpringWorks Submits NDA For Mirdametinib In NF1-PN Treatment
01 Jul 2024 //
GLOBENEWSWIRE
GSK axes Blenrep combo studies with SpringWorks` Ogsiveo
11 Jun 2024 //
FIERCE PHARMA
SpringWorks: Attending Goldman Sachs Global Healthcare Conference
05 Jun 2024 //
GLOBENEWSWIRE
Springworks Data Presentation: 2024 Asco Annual Meeting Scheduled
23 May 2024 //
GLOBENEWSWIRE
SpringWorks At BofA Securities Healthcare Conference 2024
08 May 2024 //
GLOBENEWSWIRE
SpringWorks Q1 2024 Results, Business Updates
02 May 2024 //
GLOBENEWSWIRE
SpringWorks Abstracts Accepted for ASCO 2024 Presentation
24 Apr 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics Q1 2024 Results On May 2
18 Apr 2024 //
GLOBENEWSWIRE
SpringWorks Initiates Rolling Submission of NDA to the FDA for Mirdametinib
04 Mar 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics Announces EMA Validation for MAA of Nirogacestat
29 Feb 2024 //
GLOBENEWSWIRE
SpringWorks Announces EMA Validation for MAA of Nirogacestat
29 Feb 2024 //
PRESS RELEASE
SpringWorks Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics to Present at Upcoming Investor Conferences
22 Feb 2024 //
GLOBENEWSWIRE
Where Does SpringWorks Stock Fall in the Biotechnology Field
16 Feb 2024 //
INVESTOR OBSERVER
SpringWorks Therapeutics to Participate in 6th Annual Biotechnology Conference
31 Jan 2024 //
GLOBENEWSWIRE
SpringWorks Therapeutics Highlights 2023 Accomplishments
08 Jan 2024 //
GLOBENEWSWIRE
SpringWorks to Present at the 42nd Annual J.P. Morgan Healthcare Conference
21 Dec 2023 //
GLOBENEWSWIRE
SpringWorks Announces Closing of Upsized Public Offering of Common Stock
08 Dec 2023 //
GLOBENEWSWIRE
SpringWorks Announces Pricing of Upsized Public Offering of Common Stock
05 Dec 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics Announces Proposed Public Offering of Common Stock
04 Dec 2023 //
GLOBENEWSWIRE
SpringWorks to Participate in the 6th Annual Evercore ISI HealthCONx Conference
29 Nov 2023 //
GLOBENEWSWIRE
SpringWorks` non-cancerous tumor drug to be priced at $29,000 per month in US
28 Nov 2023 //
REUTERS
FDA Approves First Therapy for Rare Type of Non-Cancerous Tumors
28 Nov 2023 //
FDA
SpringWorks Announces Positive Results from Phase 2b ReNeu Trial of Mirdametinib
16 Nov 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
GLOBENEWSWIRE
SpringWorks Announces Presentation of Data from Phase 3 Trial of Nirogacestat
01 Nov 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics Appoints Dr. Tai-An Lin as Chief Scientific Officer
11 Sep 2023 //
GLOBENEWSWIRE
SpringWorks fixes `minor data handling error` after March Form 483
21 Aug 2023 //
ENDPTS
SpringWorks Therapeutics Reports Second Quarter 2023 Financial Results
02 Aug 2023 //
GLOBENEWSWIRE
SpringWorks stalled in pre-launch mode for brand communications
06 Jul 2023 //
ENDPTS
SpringWorks to Participate in Goldman Sachs 44th Annual Healthcare Conference
07 Jun 2023 //
GLOBENEWSWIRE
US FDA delays decision on SpringWorks Therapeutics` tumor treatment
05 Jun 2023 //
REUTERS
SpringWorks achieves complete enrolment in OvGCT therapy trial
31 May 2023 //
CLINICAL TRIALS ARENA
SpringWorks Therapeutics Announces Full Enrollment of Phase 2 Trial
30 May 2023 //
GLOBENEWSWIRE
SpringWorks Announces Presentation of Data from PIII DeFi Trial of Nirogacestat
25 May 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics to Participate in the TD Cowen 4th Annual Oncology
24 May 2023 //
GLOBENEWSWIRE
SpringWorks Announces Presentations of Nirogacestat with BCMA-Directed Therapies
11 May 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics Reports 1Q 2023 FYR and Recent Business Highlights
03 May 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics to Participate in the Bank of America Securities 2023
02 May 2023 //
GLOBENEWSWIRE
MapKure, SpringWorks and BeiGene Present Clinical Data on BGB-3245
17 Apr 2023 //
GLOBENEWSWIRE
SpringWorks & BeiGene Present Clinical Data on Lifirafenib, combo Mirdametinib
17 Apr 2023 //
GLOBENEWSWIRE
AACR 2023 – Moderna`s immunotherapeutic splash
21 Mar 2023 //
PRESS RELEASE
SpringWorks Announces Publication of Phase 3 DeFi Trial Evaluating Nirogacestat
08 Mar 2023 //
PRESS RELEASE
SpringWorks to Participate in the Cowen 43rd Annual Health Care Conference
01 Mar 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics Reports Q4 and Full-Year 2022 Financial Results
28 Feb 2023 //
PRESS RELEASE
Pfizer spinout SpringWorks gets FDA priority review for lead drug
28 Feb 2023 //
ENDPTS
SpringWorks Announces FDA Acceptance and Priority Review of NDA for Nirogacestat
27 Feb 2023 //
GLOBENEWSWIRE
SpringWorks to present at the 41st Annual J.P. Morgan Healthcare Conference
09 Jan 2023 //
GLOBENEWSWIRE
SpringWorks Therapeutics to Present at the 41st Annual J.P. Morgan Conference
03 Jan 2023 //
GLOBENEWSWIRE
